Literature DB >> 1321792

The prostaglandin E1 analogue, misoprostol, regulates inflammatory cytokines and immune functions in vitro like the natural prostaglandins E1, E2 and E3.

D R Haynes1, M W Whitehouse, B Vernon-Roberts.   

Abstract

We examined whether some immune functions related to the action and production of cytokines could be regulated by the natural prostaglandins E (PGE) and the PGE1 (ester) analogue, Misoprostol. PGE1,2,3 and Misoprostol inhibited: (1) the mitogenic activity of interleukin-1 (IL-1) for mouse thymocytes; (2) spreading of mouse macrophages on glass; (3) tumour necrosis factor (TNF) (alpha and beta) production by human peripheral blood mononuclear cells and rat macrophages; (4) IL-1 production by rat and mouse peritoneal macrophages; and (5) interferon-gamma (IFN-gamma) production by human peripheral blood mononuclear cells. These PGE had little effect on IL-1 production by human monocytes. By contrast, they all enhanced IL-6 production by rat and mouse macrophages and human monocytes. These effects were noted at concentrations below 500 nM (even as low as 10 nM). The relative potency of the prostanoids tested for both inhibitory and stimulatory effects was PGE1 = PGE2 = or greater than PGE3 greater than Misoprostol greater than PGA2 much greater than PGF1-alpha = PGF2-alpha = PGD2 (no effect). There is strong evidence that PGE1,2,3 and Misoprostol bind to the same receptor(s) and trigger the second messenger, cAMP, since dibutyryl cAMP (a lipophilic analogue of cAMP) had the same effects as the PGE. These PGE also induced elevated intracellular cAMP levels in and competed with [3H]PGE2 for binding to human and rat cells with the same relative potencies as described above.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1321792      PMCID: PMC1421541     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  28 in total

1.  Immunosuppressive effect of misoprostol: a new synthetic prostaglandin E1 analogue.

Authors:  J C Wiederkehr; L Dumble; R Pollak; M Moran
Journal:  Aust N Z J Surg       Date:  1990-02

Review 2.  Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF).

Authors:  S Akira; T Hirano; T Taga; T Kishimoto
Journal:  FASEB J       Date:  1990-08       Impact factor: 5.191

3.  The pharmacologic regulation of interleukin-1 production: the role of prostaglandins.

Authors:  I G Otterness; M L Bliven; J D Eskra; M Reinke; D C Hanson
Journal:  Cell Immunol       Date:  1988-07       Impact factor: 4.868

4.  A simple sensitive bioassay for interleukin-1 which is unresponsive to 10(3) U/ml of interleukin-2.

Authors:  A J Gearing; C R Bird; A Bristow; S Poole; R Thorpe
Journal:  J Immunol Methods       Date:  1987-05-04       Impact factor: 2.303

5.  Effect of gold salt treatment on the receptor binding activity of monocytes and macrophages isolated from rats with adjuvant arthritis.

Authors:  D R Haynes; I R Garrett; B Vernon-Roberts
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

6.  Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate.

Authors:  P J Knudsen; C A Dinarello; T B Strom
Journal:  J Immunol       Date:  1986-11-15       Impact factor: 5.422

7.  Interleukin 4 activates human B lymphocytes via transient inositol lipid hydrolysis and delayed cyclic adenosine monophosphate generation.

Authors:  M Finney; G R Guy; R H Michell; J Gordon; B Dugas; K P Rigley; R E Callard
Journal:  Eur J Immunol       Date:  1990-01       Impact factor: 5.532

8.  Transcription, translation and secretion of interleukin 1 and tumor necrosis factor: effects of tebufelone, a dual cyclooxygenase/5-lipoxygenase inhibitor.

Authors:  S P Sirko; R Schindler; M J Doyle; S M Weisman; C A Dinarello
Journal:  Eur J Immunol       Date:  1991-02       Impact factor: 5.532

9.  Studies on the characterisation of prostanoid receptors: a proposed classification.

Authors:  I Kennedy; R A Coleman; P P Humphrey; G P Levy; P Lumley
Journal:  Prostaglandins       Date:  1982-11

10.  Effect of increasing the dietary (n-3) to (n-6) polyunsaturated fatty acid ratio on murine liver and peritoneal cell fatty acids and eicosanoid formation.

Authors:  K S Broughton; J Whelan; I Hardardottir; J E Kinsella
Journal:  J Nutr       Date:  1991-02       Impact factor: 4.798

View more
  25 in total

1.  Professor Barrie Vernon-Roberts, AO, MD, BSc, PhD, FRCPath, FRCPA, FAOrthA (Hon), FRS.SA.

Authors:  K D Rainsford; D R Haynes
Journal:  Inflammopharmacology       Date:  2013-07-04       Impact factor: 4.473

2.  Neither vaginal nor buccal administration of 800 μg misoprostol alters mucosal and systemic immune activation or the cervicovaginal microbiome: a pilot study.

Authors:  Spyros A Kalams; Lisa M Rogers; Rita M Smith; Louise Barnett; Katie Crumbo; Shonda Sumner; Naomi Prashad; Kyle Rybczyk; Ginger Milne; Scot E Dowd; Erica Chong; Beverly Winikoff; David M Aronoff
Journal:  Eur J Contracept Reprod Health Care       Date:  2016-09-16       Impact factor: 1.848

3.  A six week double blind, placebo controlled, crossover study of the effect of misoprostol in the treatment of aspirin sensitive asthma.

Authors:  W Wasiak; M Szmidt
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

4.  Complete prevention of the clinical expression of adjuvant-induced arthritis in rats by cyclosporin-A and lobenzarit: the regulation of lymph node cell populations and cytokine production.

Authors:  D R Haynes; S J Gadd; M W Whitehouse; G Mayrhofer; B Vernon-Roberts
Journal:  Inflamm Res       Date:  1996-04       Impact factor: 4.575

5.  A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy.

Authors:  Rajesh V Lalla; Gary B Gordon; Mark Schubert; Sol Silverman; Mark Hutten; Stephen T Sonis; Francis LeVeque; Douglas E Peterson
Journal:  Support Care Cancer       Date:  2011-10-01       Impact factor: 3.603

6.  Does perioperative prostaglandin E1 affect survival of patients with esophageal cancer?

Authors:  Fahimeh Farrokhnia; Jalil Makarem; Habibollah Mahmoodzadeh; Nazanin Andalib
Journal:  World J Gastrointest Surg       Date:  2012-12-27

7.  Eicosapentaenoic acid suppression of systemic inflammatory responses and inverse up-regulation of 15-deoxyΔ(12,14) prostaglandin J2 production.

Authors:  Jillian Davidson; Warren Higgs; Dino Rotondo
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

8.  Misoprostol, a prostaglandin E1 analogue, inhibits basic calcium phosphate crystal-induced mitogenesis and collagenase accumulation in human fibroblasts.

Authors:  G M McCarthy; P G Mitchell; H S Cheung
Journal:  Calcif Tissue Int       Date:  1993-06       Impact factor: 4.333

9.  Misoprostol impairs female reproductive tract innate immunity against Clostridium sordellii.

Authors:  David M Aronoff; Yibai Hao; Jooho Chung; Nicole Coleman; Casey Lewis; Camila M Peres; Carlos H Serezani; Gwo-Hsiao Chen; Nicolas Flamand; Thomas G Brock; Marc Peters-Golden
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

10.  Expression of recombinant feline tumor necrosis factor is toxic to Escherichia coli.

Authors:  C M Otto; F Niagro; X Su; C A Rawlings
Journal:  Clin Diagn Lab Immunol       Date:  1995-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.